Literature DB >> 22955290

Development of prognostic tools in pulmonary arterial hypertension: lessons from modern day registries.

Raymond L Benza1, Mardi Gomberg-Maitland, Adaani E Frost, Robert P Frantz, Marc Humbert, Michael D McGoon.   

Abstract

Pulmonary arterial hypertension (PAH) is characterised by increased pressure in the pulmonary arteries leading to right-sided ventricular failure, and death. Identification of factors that affect patient survival is important to improve patient management and outcomes. The first registry to evaluate survival and develop a prognostic model was the National Institutes of Health (NIH) registry in 1981. Importantly this prognostic model is based on data collected prior to availability of PAH-targeted therapies and does not reflect survival rates for treated patients. Since the 1980s, however, four modern registries of PAH now exist which compensate for the NIH equations shortcomings and include the French National registry, Pulmonary Hypertension Connection registry, the Mayo registry, and the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL). The similarities and difference in these registries are highlighted in this review and although similar in many respects, the four registries vary in patient population, including the numbers of newly and previously diagnosed patients, as well as the era of observation, period of survival, and timing of assessment of potential predictive factors. Despite this, the predictive factors identified in each registry and described in detail within the body of this manuscript share surprising homology in that disease aetiology, patient gender and factors reflective of right heart failure are integral in depicting survival. Future modifications of modern prognostic equations should be an ongoing goal of the PAH community in order to provide increased accuracy with identification of novel risk factors and prediction of disease course.

Entities:  

Mesh:

Year:  2012        PMID: 22955290     DOI: 10.1160/TH11-11-0821

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  4 in total

Review 1.  Biomarkers in pulmonary arterial hypertension.

Authors:  Julie L Rosenthal; Miriam S Jacob
Journal:  Curr Heart Fail Rep       Date:  2014-12

Review 2.  Health Disparities in Patients with Pulmonary Arterial Hypertension: A Blueprint for Action. An Official American Thoracic Society Statement.

Authors:  Arunabh Talwar; Joe G N Garcia; Halley Tsai; Matthew Moreno; Tim Lahm; Roham T Zamanian; Roberto Machado; Steven M Kawut; Mona Selej; Stephen Mathai; Laura Hoyt D'Anna; Sonu Sahni; Erik J Rodriquez; Richard Channick; Karen Fagan; Michael Gray; Jessica Armstrong; Josanna Rodriguez Lopez; Vinicio de Jesus Perez
Journal:  Am J Respir Crit Care Med       Date:  2017-10-15       Impact factor: 21.405

3.  Elevated plasma CXCL12α is associated with a poorer prognosis in pulmonary arterial hypertension.

Authors:  Brian N McCullagh; Christine M Costello; Lili Li; Caroline O'Connell; Mary Codd; Allan Lawrie; Allison Morton; David G Kiely; Robin Condliffe; Charles Elliot; Paul McLoughlin; Sean Gaine
Journal:  PLoS One       Date:  2015-04-09       Impact factor: 3.240

4.  Clinical trial design in phase 2 and 3 trials for pulmonary hypertension.

Authors:  Sylvia Nikkho; Peter Fernandes; R James White; Chunqin Cq Deng; Harrison W Farber; Paul A Corris
Journal:  Pulm Circ       Date:  2020-07-20       Impact factor: 3.017

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.